Retinal Pigment Epithelium Injury in Pentosan Polysulfate Exposure: Morphologic Changes, Phagocytic Deficits, and Mitochondrial Dysfunction

This study demonstrates that long-term pentosan polysulfate (PPS) exposure induces retinal pigment epithelium injury by impairing mitochondrial respiration, disrupting protective mechanisms against oxidative stress, and causing structural and functional deficits including reduced phagocytosis and increased cell death.

The Gist

The Big Picture: A Drug with a Hidden Side Effect

Imagine a medication called Pentosan Polysulfate (PPS). It's been used for decades to treat a painful bladder condition (Interstitial Cystitis). It's like a reliable workhorse that helps millions of people feel better.

However, in recent years, doctors noticed something scary: people taking this drug for a long time were developing a specific type of blindness. Their eyes were getting damaged, specifically in the back of the eye where the "retinal pigment epithelium" (RPE) lives. Think of the RPE as the ground crew for a stadium (the retina). The ground crew's job is to clean up trash, feed the players (photoreceptors), and keep the lights (mitochondria) working.

This study asked: "How exactly is this drug hurting the ground crew?"

The Experiment: Putting the Cells in a Test Tube

The researchers took human eye cells (RPE cells) and put them in a lab dish. They then "fed" these cells different amounts of the drug, from a tiny sprinkle to a heavy dose, for three days. They watched what happened to the cells' internal machinery.

Here is what they found, broken down into simple concepts:

1. The Power Plants Are Failing (Mitochondrial Dysfunction)

Inside every cell, there are tiny power plants called mitochondria. They burn fuel to create electricity (energy) for the cell to work.

• What happened: When the drug was added, the power plants started smoking. They produced too much "exhaust" (called reactive oxygen species or ROS), which is like toxic smoke that damages the machinery.
• The Result: The power plants stopped working efficiently. They couldn't generate enough energy (ATP) to keep the cell running. It's like a car engine that is sputtering and smoking, unable to drive the car forward.

2. The Cleanup Crew Got Confused (Protective Mechanisms)

Normally, when a cell gets stressed, it has a "cleanup crew" (autophagy and mitophagy) that fixes broken parts or throws them away. It also has a "manager" (PGC-1α) that orders new power plants to be built.

• What happened: The drug messed up the instructions.
  • At low doses, the cell tried to panic and build more power plants, but the instructions were garbled.
  • At high doses, the cleanup crew stopped working entirely. The cell was drowning in toxic smoke and broken machinery, with no one to clean it up.
  • Interestingly, the cell tried to sound the alarm (increasing a marker called PINK1) as time went on, but it was too little, too late.

3. The Cells Lost Their Shape (Morphology Changes)

Healthy RPE cells look like neat, hexagonal tiles on a floor. They fit together perfectly.

• What happened: Under the influence of the drug, the cells started stretching out and looking weird. They became long and thin, losing their neat shape.
• The Analogy: Imagine a team of dancers in perfect formation. Suddenly, the music changes, and they all start running in different directions, stretching out and losing their formation. This is a sign of "Epithelial-Mesenchymal Transition" (EMT), which is basically the cell saying, "I'm so stressed I'm changing my whole identity," which is bad for a cell that needs to stay in one spot to do its job.

4. The Trash Collection Stopped (Phagocytosis Failure)

The RPE's most important job is to eat up old, worn-out parts of the eye (photoreceptor outer segments) every day. If they don't eat this trash, the eye gets clogged and vision fails.

• What happened: The drug-treated cells stopped eating the trash. They were too weak and too damaged to do their job.
• The Result: The "ground crew" stopped cleaning the stadium. The trash piled up, leading to the vision loss seen in patients.

5. The Final Blow: Cell Death

When the energy ran out, the trash piled up, and the shape was lost, the cells simply gave up.

• What happened: At higher doses of the drug, the cells died. The researchers saw this by staining the dead cells red. It's like the stadium lights finally going out because the power plant exploded.

The Takeaway

This study acts like a detective story. It didn't just say "the drug is bad"; it showed why.

It turns out that Pentosan Polysulfate attacks the mitochondria (the power plants) of the eye's support cells. This causes a chain reaction:

1. The cells run out of energy.
2. They can't clean up their own trash.
3. They lose their shape.
4. They eventually die.

Why does this matter?
Now that we know the drug attacks the mitochondria, doctors and scientists have a new target. Future treatments might focus on protecting the mitochondria or giving the cells extra energy to fight off the drug's effects, potentially saving the vision of people who need this medication for their bladder pain.

In short: The drug is a double-edged sword. It fixes the bladder but breaks the engine of the eye. This research helps us understand how to fix the engine so we don't have to lose our sight.

Technical Summary

1. Problem Statement

Pentosan Polysulfate (PPS) is a semisynthetic sulfated polysaccharide FDA-approved for interstitial cystitis. Long-term use has been linked to PPS maculopathy, a vision-threatening condition characterized by retinal pigment epithelium (RPE) damage, pigmentary changes, and progressive vision loss. While the clinical presentation is known, the pathophysiology remains poorly understood.

• Clinical Gap: There are no known treatments to halt disease progression.
• Hypothesis: Based on similarities to mitochondrial maculopathies (e.g., MIDD), the study hypothesizes that PPS toxicity is mediated by a primary insult to RPE mitochondria, leading to oxidative stress, energy failure, and subsequent cellular dysfunction.

2. Methodology

The study utilized an in vitro cell culture model using human ARPE-19 cells (a retinal pigment epithelial cell line).

• Experimental Design:
  • Doses: Cells were treated with PPS at concentrations of 0, 0.1, 1.0, and 10.0 mg/mL.
  • Duration: Primary experiments were conducted over 72 hours, with time-course analyses (24, 48, 72 hours) for specific markers.
• Key Assays & Techniques:
  • Mitochondrial ROS: Live-cell imaging with MitoSOX Red to quantify mitochondrial superoxide accumulation.
  • Mitochondrial Respiration: Seahorse XF Cell Mito Stress Test to measure Oxygen Consumption Rate (OCR), basal respiration, maximal respiration, and ATP production.
  • Energy Sensing: Western blotting for AMPK and phosphorylated AMPK (pAMPK).
  • Protective Mechanisms (Gene & Protein):
    • qPCR: Analysis of mitochondrial biogenesis markers (PGC-1α, SIRT1) and mitophagy initiator (PINK1).
    • Western Blot: Analysis of autophagy/mitophagy markers (LC3, p62), mitochondrial mass (TOM20), and EMT markers (ZEB1, TWIST, Vimentin).
  • Functional Assays:
    • Phagocytosis: pHrodo™ Red E. coli BioParticles assay to assess RPE ability to engulf and digest particles.
    • Cell Viability: Ethidium Homodimer assay to detect cell death.
  • Morphology: Brightfield microscopy and ImageJ analysis to measure cell aspect ratio (elongation).

3. Key Results

A. Mitochondrial Dysfunction and Oxidative Stress

• ROS Accumulation: PPS exposure caused a significant, dose-dependent increase in mitochondrial superoxide (MitoSOX signal) at 1.0 and 10.0 mg/mL.
• Respiratory Failure: Seahorse assays revealed a significant decrease in basal respiration (at 10 mg/mL) and maximal respiration (at all doses) after 72 hours.
• ATP Depletion: There was a significant reduction in ATP production across all PPS concentrations.
• Energy Sensor Response: Despite the drop in ATP, the active form of the energy sensor pAMPK did not increase, suggesting a failure in the cell's compensatory energy response mechanisms.

B. Disruption of Protective Mechanisms

• Mitochondrial Biogenesis:
  • Transcriptional Level: PGC-1α mRNA decreased at low doses (0.1 mg/mL) but increased at high doses (10 mg/mL). SIRT1 mRNA increased at 1.0 and 10.0 mg/mL.
  • Translational Mismatch: Protein levels did not consistently mirror mRNA trends, indicating a disconnect between transcriptional attempts to repair mitochondria and actual protein synthesis.
• Mitophagy (Mitochondrial Clearance):
  • PINK1 (a mitophagy initiator) expression increased significantly with duration of exposure (24h to 72h), suggesting a time-dependent accumulation of mitochondrial damage.
  • LC3 and p62 (autophagy markers) showed a complex trend: increased at low doses (0.1 mg/mL) but decreased at high doses (10 mg/mL), suggesting a collapse of the autophagic flux at toxic concentrations.
  • TOM20 (mitochondrial mass) increased at 0.1 mg/mL but decreased at 1.0 mg/mL, indicating mitochondrial loss at higher toxicity levels.

C. Morphological and Functional Changes

• EMT-like Transition: High doses of PPS (1.0 and 10.0 mg/mL) caused a significant increase in cell aspect ratio (cell elongation). qPCR showed upregulation of EMT transcription factors ZEB1 and TWIST at 10 mg/mL. However, Vimentin protein levels remained relatively stable, suggesting an early or partial EMT state.
• Phagocytic Deficit: The pHrodo assay demonstrated a significant impairment in phagocytosis at higher PPS doses, likely due to the lack of ATP required for the energy-intensive process of engulfing photoreceptor outer segments.
• Cell Death: Ethidium Homodimer assays confirmed a significant increase in cell death at 1.0 and 10.0 mg/mL doses.

4. Key Contributions

1. Mechanistic Insight: The study provides the first detailed molecular evidence that PPS toxicity in RPE cells is driven primarily by mitochondrial dysfunction, specifically the accumulation of superoxide and the collapse of respiratory capacity.
2. Failure of Compensatory Pathways: It highlights that while cells attempt to upregulate protective genes (PGC-1α, SIRT1, PINK1) in response to PPS, these mechanisms fail at the protein level or are overwhelmed, leading to a "protective collapse."
3. Functional Correlation: The study links mitochondrial energy failure directly to phagocytic dysfunction, a critical RPE function required for retinal health.
4. Morphological Evidence: It documents PPS-induced morphological changes (elongation/EMT markers) that mirror clinical findings of RPE stress and atrophy.

5. Significance and Future Directions

• Clinical Relevance: The findings explain the phenotypic similarities between PPS maculopathy and genetic mitochondrial diseases (like MIDD), validating the "mitochondrial insult" hypothesis.
• Therapeutic Implications: The identification of mitochondrial respiration failure and ROS accumulation suggests that future therapeutic strategies for PPS maculopathy should focus on mitoprotection, antioxidant therapy, or agents that restore mitochondrial biogenesis.
• Limitations: The study used an immortalized cell line (ARPE-19) rather than primary or iPSC-derived RPE, and the in vitro dosing may not perfectly mimic the cumulative in vivo exposure of patients.
• Conclusion: Long-term PPS exposure overwhelms RPE mitochondrial defenses, leading to energy failure, oxidative stress, impaired phagocytosis, and eventual cell death. This establishes mitochondrial health as a critical target for understanding and potentially treating PPS maculopathy.